论文部分内容阅读
目的分析髓样分化因子88(My D88)在卵巢癌组织中的表达及其与患者临床病理特征和预后的关系。方法收集上皮性卵巢癌患者的癌组织56例和癌旁正常组织26例为研究对象。用免疫组织化学法检测癌组织和癌旁正常组织中My D88的表达水平,分析My D88的表达与患者临床病理特征及患者预后的相关性。结果 My D88在癌组织和癌旁组织中的表达率分别为67.85%和23.08%,差异有统计学意义(P<0.05);My D88阳性表达与患者的临床分期和淋巴结转移相关(P<0.05),与患者的年龄(P>0.05)、病理分级(P>0.05)、肿瘤大小(P>0.05)及组织分级(P>0.05)等临床病理特征无关。My D88阳性和阴性患者的5年累计生存率分别为21.63%,49.32%;中位生存期分别为26.52,48.94个月,差异均有统计学意义(P<0.05)。结论 My D88在卵巢癌组织中表达率较高,其可能与卵巢癌的发生发展及转移有关,并可作为预后的分子标志物。
Objective To analyze the expression of myeloid differentiation factor 88 (My D88) in ovarian cancer and its relationship with clinicopathological features and prognosis. Methods 56 cases of epithelial ovarian cancer patients and 26 cases of adjacent normal tissues were collected as research object. The expression of My D88 was detected by immunohistochemistry in cancer tissues and adjacent normal tissues. The relationship between the expression of My D88 and clinicopathological characteristics and prognosis was analyzed. Results The positive expression rates of My D88 in cancer tissues and paracancerous tissues were 67.85% and 23.08%, respectively (P <0.05). The positive expression of My D88 was correlated with the clinical stage and lymph node metastasis ) Was not related to the clinicopathological features such as age (P> 0.05), pathological grade (P> 0.05), tumor size (P> 0.05) and histological grade (P> 0.05) The 5-year cumulative survival rates of My D88-positive and -negative patients were 21.63% and 49.32%, respectively. The median survival time was 26.52 and 48.94 months respectively, with statistical significance (P <0.05). Conclusion My D88 is highly expressed in ovarian cancer, which may be related to the development and metastasis of ovarian cancer and may be used as a molecular marker of prognosis.